Skip To Main Content
Jennifer Kwon on Muck Rack

Jennifer Kwon

As seen in: Amazon Web Services, Nature, Wiley Online Library, Al Jazeera English, Cell Press, Lexology, CGTLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jennifer

Contact Jennifer, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial - Nature Medicine

|
By Jennifer Kwon, Tamaki Kato, Liesbeth De Waele, Ian Woodcock, Crystal Proud, Gemma Williams
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-04119-2, published online 8 December 2025. In the version of the article initially published, in the second paragraph of the “Safety” section, the text “one on the day of gastronomy surgery” has been amended to “one on the day of percutaneous endoscopic gastrostomy” in the HTML and PDF versions of the article.
Open in Who Shared View Duplicates (8) Issue with article?

KRAS Footprints in the Skin: Leveraging Targeted Therapy for Unresectable Intra‐Cerebral AVM

|
By Donglin Zhang, Jennifer Kwon, Beverly Aagaard-Kienitz, Susan Rebsamen
| Wiley Online Library Verified
To the Editors, A 15-year-old female presented to the multidisciplinary vascular anomalies clinic with a cerebral arteriovenous malformation (AVM) involving the bilateral thalami and basal ganglia, initially discovered 8 years prior during evaluation for meningitis. Her course was notable for progressive neurologic decline, including worsening fatigue, gait instability, urinary incontinence, and right-sided dystonia.
Open in Who Shared Issue with article?

Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial - Nature Medicine

|
By Jennifer Kwon, Tamaki Kato, Liesbeth De Waele, Ian Woodcock, Crystal Proud, Gemma Williams
| Nature Verified
Abstract Intrathecal onasemnogene abeparvovec (OAV101 IT) may enable a one-time gene transfer therapy, addressing an unmet need across the broader spinal muscular atrophy (SMA) population. STRENGTH (NCT05386680) was a 52-week, phase 3b, single-arm, open-label, multicenter study evaluating OAV101 IT in participants with SMA aged 2 to <18 years who discontinued nusinersen or risdiplam. The primary objective was safety/tolerability.
Open in Who Shared Issue with article?
See all 12 articles